[
  {
    "question": "Patient has fracture in the acetabulum and noticed numbness on the dorsum of the foot, with weak dorsiflexion where is the lesion",
    "option_a": "(Lateral aspect of the sciatic nerve) is correct because it directly correlates with the deficits in dorsiflexion and dorsal foot sensation. Option B (Medial aspect) would involve tibial nerve deficits (plantarflexion and plantar sensory loss). Option C (Sciatic trunk) would cause a combined deficit affecting both tibial and peroneal distributions\u2014unlike the isolated findings observed.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question tests the understanding of sciatic nerve anatomy. The sciatic nerve divides into two major components: the tibial nerve (medial) and the common peroneal nerve (lateral). The lateral fibers, which form the common peroneal nerve, are responsible for dorsiflexion of the foot and sensation over the dorsum. Trauma from an acetabular fracture may injure the lateral aspect of the sciatic nerve, damaging the fibers that continue as the common peroneal nerve. This results in weakness of the dorsiflexors (leading to foot drop) and sensory loss over the dorsum of the foot. In contrast, injury to the medial component (tibial nerve) would affect plantarflexion and the sensation of the plantar surface. A patient with an acetabular fracture presenting with numbness on the dorsum of the foot and weak dorsiflexion directly points to involvement of the common peroneal portion of the sciatic nerve. The selective motor and sensory findings help to localize the lesion to the lateral aspect of the nerve rather than a more diffuse injury. Diagnosis is based on clinical evaluation and confirmation via nerve conduction studies (NCS) and electromyography (EMG). Differential diagnoses include isolated common peroneal nerve neuropathy (often seen at the fibular head) and a more proximal sciatic nerve injury. The context of a pelvic fracture, however, makes injury to the sciatic nerve more likely. Management involves addressing the fracture (often surgical stabilization) and monitoring for nerve recovery. Early physical and occupational therapy may be instituted. In cases of persistent foot drop, orthotic devices (e.g., ankle-foot orthosis) are recommended. In pregnant patients, careful imaging alternatives (like MRI without contrast) are preferred, and anesthesia considerations are adjusted to protect maternal and fetal health. Option A (Lateral aspect of the sciatic nerve) is correct because it directly correlates with the deficits in dorsiflexion and dorsal foot sensation. Option B (Medial aspect) would involve tibial nerve deficits (plantarflexion and plantar sensory loss). Option C (Sciatic trunk) would cause a combined deficit affecting both tibial and peroneal distributions\u2014unlike the isolated findings observed. 1. A foot drop with dorsal foot numbness should prompt evaluation of the common peroneal nerve involvement. 2. In pelvic fractures, always consider possible sciatic nerve injury. 3. Differentiation between tibial and common peroneal deficits is essential for localization. Recent trauma and nerve injury guidelines emphasize early neurophysiological studies to assess nerve function post-injury. Multidisciplinary management involving orthopedics, neurology, and rehabilitation is advised to optimize recovery.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario about MMN, severe weakness no atrophy asking about dx, but no ncs finding",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune-mediated neuropathy characterized by slowly progressive, asymmetric pure motor weakness. A key diagnostic marker is conduction block on nerve conduction studies. MMN is believed to result from immune-mediated demyelination specifically affecting motor nerves, leading to conduction block. The absence of conduction block, despite clinical motor weakness, makes the diagnosis of MMN less likely, which is why electrophysiological evidence is critical. Patients typically present with asymmetric, distal limb weakness without significant muscle atrophy early in the disease. The absence of conduction block on nerve conduction studies challenges the diagnosis, as it is a hallmark finding in MMN. The diagnostic workup includes detailed neurological examination, nerve conduction studies, and sometimes testing for anti-GM1 antibodies. Differential diagnoses include amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other neuropathies. ALS, for example, shows combined UMN and LMN signs with denervation on EMG but without conduction block. The first-line treatment for MMN is intravenous immunoglobulin (IVIg). Immunosuppressive therapies are generally less effective. In pregnant or lactating patients, IVIg is considered safe and is preferred over many immunosuppressants due to a more favorable risk profile. The option marked as 'None' (assumed to be letter C) is correct in this scenario because the lack of electrophysiological conduction block rules out a definitive diagnosis of MMN. Alternative options such as MND, CIDP, or ALS either have different electrophysiological profiles or are characterized by additional findings (e.g., sensory involvement or combined UMN/LMN signs). 1. Conduction block is the electrodiagnostic hallmark of MMN \u2013 its absence calls the diagnosis into question. 2. MMN typically spares sensory nerves, unlike other neuropathies. 3. IVIg is the cornerstone of treatment in confirmed MMN cases. Recent studies stress the importance of electrophysiological tests in diagnosing MMN and differentiating it from other motor neuropathies. Updated guidelines recommend early IVIg therapy in confirmed cases to improve outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario patient has progressive hand muscle weakness with severe atrophy, planters upgoing in LL dx",
    "option_a": "(ALS) is correctly identified. The other options (e.g., myelitis, myelopathy) do not typically present with the combination of severe focal LMN degeneration (marked atrophy) alongside clear UMN signs (plantar upgoing) in a progressive pattern.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "The question highlights a classic presentation of Amyotrophic Lateral Sclerosis (ALS), characterized by the coexistence of upper motor neuron (UMN) and lower motor neuron (LMN) signs within the same region. ALS is a neurodegenerative disorder involving the progressive loss of both UMNs (in the motor cortex) and LMNs (in the anterior horns of the spinal cord). This dual involvement leads to muscle weakness, atrophy, and spasticity, with pathological evidence of motor neuron degeneration. Patients with ALS may present initially with progressive hand muscle weakness and atrophy (LMN signs) alongside hyperreflexia and positive Babinski signs (UMN signs), such as an upgoing plantar reflex in the lower limbs. This combination is highly suggestive of ALS. Diagnosis is clinical, supported by electrophysiological studies (EMG/NCV) which typically reveal widespread denervation. Differential diagnoses include cervical spondylotic myelopathy (which may present with UMN signs without the pronounced LMN atrophy seen in ALS) and other motor neuron diseases. Detailed neuroimaging is also used to rule out structural lesions. While there is no cure for ALS, management focuses on prolonging survival and palliating symptoms. The first-line pharmacological treatment is riluzole, which modestly extends survival, and edaravone may be used in select patients. A multidisciplinary approach is essential, including physical therapy, nutrition support, speech therapy, and respiratory care. In pregnancy, the use of riluzole is generally avoided unless absolutely necessary, and alternatives or supportive care are considered. Option A (ALS) is correctly identified. The other options (e.g., myelitis, myelopathy) do not typically present with the combination of severe focal LMN degeneration (marked atrophy) alongside clear UMN signs (plantar upgoing) in a progressive pattern. 1. The presence of both UMN and LMN signs in a single region is a red flag for ALS. 2. Progressive hand weakness with significant atrophy and hyperreflexia is highly indicative of ALS. 3. Early multidisciplinary intervention plays a critical role in managing ALS. Recent research continues to explore disease-modifying therapies for ALS. Current guidelines emphasize early diagnosis, multidisciplinary care, and supportive treatment measures, while riluzole remains the only drug with proven survival benefit in many regions.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Moderate muscle weakness, hyperkeratosis on the hand lung crackles",
    "option_a": "(MDA",
    "option_b": "(Anti",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a patient with moderate muscle weakness, mechanic's hands (hyperkeratosis on the hand), and lung crackles \u2013 a constellation highly suggestive of anti-synthetase syndrome, an overlap syndrome within the inflammatory myopathies. Anti-synthetase syndrome is an autoimmune condition characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies (most commonly anti-Jo-1). The immune-mediated process leads to inflammation in muscles (resulting in myositis), characteristic skin changes (mechanic's hands), and interstitial lung disease (manifesting as lung crackles). By contrast, anti-MDA-5 antibodies are typically seen in patients with clinically amyopathic dermatomyositis and are associated with rapidly progressive interstitial lung disease, often with less prominent myositis and with ulcerative skin lesions rather than mechanic\u2019s hands. Patients with anti-synthetase syndrome often present with moderate myositis, arthritis, and interstitial lung disease, along with distinctive skin findings such as hyperkeratosis and fissuring on the hands (mechanic's hands). The constellation of moderate muscle weakness, mechanic's hands, and lung crackles is characteristic for this syndrome. Diagnosis involves a combination of clinical evaluation, serologic testing for specific antibodies (e.g., anti-Jo-1 or other anti-synthetase antibodies), muscle enzyme levels, electromyography, and imaging studies such as high-resolution CT for lung involvement. Differential diagnoses include other inflammatory myopathies like dermatomyositis, especially the MDA-5 positive variant, which typically presents with minimal muscle weakness and more prominent skin ulcerations. First-line treatment for anti-synthetase syndrome includes corticosteroids to reduce inflammation, often combined with steroid-sparing immunosuppressive agents such as methotrexate, azathioprine, or mycophenolate mofetil. In patients with significant interstitial lung disease, early aggressive immunosuppressive therapy is crucial. For pregnant patients, corticosteroids remain the safest option. Azathioprine is also considered relatively safe during pregnancy, whereas agents like methotrexate are contraindicated. Management should ideally involve a multidisciplinary team including rheumatology, pulmonology, and neurology. Option A (MDA-5 antibody) is incorrect because anti-MDA-5 is associated with a form of dermatomyositis that is typically clinically amyopathic with ulcerative skin lesions rather than prominent mechanic's hands. Option B (Anti-synthetase antibody) correctly fits the clinical picture provided, making it the best choice. 1. Mechanic's hands (hyperkeratosis and fissuring on the hands) are a key clinical clue for anti-synthetase syndrome. 2. Interstitial lung disease, manifesting as lung crackles, is common in this syndrome and requires early detection and management. 3. Always correlate antibody profiles with clinical findings: anti-MDA-5 is more common in amyopathic dermatomyositis, while anti-synthetase antibodies are linked to myositis with systemic features. Recent guidelines stress the importance of early antibody testing in patients with inflammatory myopathy symptoms and ILD. Multidisciplinary care and tailored immunosuppressive therapy based on disease severity, patient comorbidities, and pregnancy status are emphasized in current treatment algorithms.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Neuromyopathies, asking about the medications",
    "option_a": "(Chloroquine) is correct since its mechanism of causing vacuolar myopathy via lysosomal dysfunction is well",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question focuses on identifying medication-induced neuromyopathy. Chloroquine is a well-known drug that can cause a toxic myopathy by interfering with lysosomal function, which is a hallmark of this type of neuromyopathy. Chloroquine accumulates within lysosomes and raises the intralysosomal pH. This disrupts normal lysosomal enzyme activity leading to impaired autophagic degradation and formation of autophagic vacuoles (often with curvilinear bodies seen on electron microscopy). Over time, these alterations lead to muscle fiber damage and vacuolar myopathy. Patients typically present with proximal muscle weakness. The vacuolar changes on muscle biopsy, along with the exposure history to chloroquine, help differentiate this condition from other medication-induced myopathies such as steroid-induced myopathy (which typically shows type II fiber atrophy without vacuoles) or statin-induced necrotizing myopathy (which involves muscle fiber necrosis without characteristic vacuolization). Diagnosis involves a careful clinical history focusing on medication exposure and correlating with symptoms. A muscle biopsy is the gold standard where the presence of autophagic vacuoles and curvilinear bodies confirms the diagnosis. Differential diagnoses include corticosteroid myopathy and statin-induced myopathy; these can be differentiated based on distinct histopathological features. The primary management is the discontinuation of the offending agent (chloroquine). Supportive measures, including physical therapy, may be used in recovery. In scenarios involving pregnant or lactating patients, the risk\u2013benefit analysis is crucial since chloroquine (while sometimes used in autoimmune diseases or malaria prophylaxis) should be used with caution and under strict monitoring if a patient already shows neuromuscular symptoms. Option A (Chloroquine) is correct since its mechanism of causing vacuolar myopathy via lysosomal dysfunction is well-established. Other potential options (which were not provided in detail) are less specific; for example, corticosteroids cause a different pattern of muscle injury and statins typically result in necrotizing rather than vacuolar myopathy. 1. Chloroquine toxicity is best identified by its classic histological finding of autophagic vacuoles with curvilinear bodies. 2. A detailed medication history is critical when evaluating a patient with proximal muscle weakness. 3. Differentiating drug-induced myopathies by their histopathological features is essential for appropriate management. Recent studies and reviews continue to support the role of chloroquine in inducing lysosome-mediated myopathies. Updated clinical guidelines emphasize the importance of recognizing drug-induced myopathies early, particularly in patients receiving chloroquine for chronic conditions, to prevent irreversible muscle damage.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient on statin had necrotizing myositis whats the cause",
    "option_a": "(Age) is incorrect because although older age increases susceptibility to myopathy, it is not a direct causative factor. Option B (Erythromycin interaction) is correct as it directly leads to increased statin levels and subsequent muscle toxicity. Other options, if provided, would similarly be less specific in explaining the necrotizing myositis in this context.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "The focus here is on identifying the precipitating factor for statin-induced necrotizing myositis. Statins, while generally safe, can cause muscle injury that may be exacerbated by drug interactions. Statins are metabolized by the cytochrome P450 system, particularly CYP3A4. Erythromycin is a potent CYP3A4 inhibitor, which leads to increased plasma concentrations of statins. The resulting elevated statin exposure can precipitate muscle toxicity, sometimes triggering an immune-mediated necrotizing process. Patients on statins who concurrently receive a CYP3A4 inhibitor like erythromycin are at greatly increased risk for severe myopathy. Clinical findings include significant proximal muscle weakness and markedly elevated creatine kinase levels. Although age is a risk factor for statin-associated myopathy, it does not directly cause the necrotizing process. The diagnosis is made by correlating the clinical presentation with the patient\u2019s medication history and laboratory findings (elevated CK levels). Differential diagnoses include primary inflammatory myopathies such as polymyositis and dermatomyositis. However, the temporal association with the introduction of an interacting drug (erythromycin) is key to distinguishing this condition. The first step in management is to discontinue both the statin and the interacting agent (erythromycin). Supportive care, including hydration and monitoring for complications, follows. In severe cases, immunosuppressive therapy may be indicated if an autoimmune component is evident. For pregnant or lactating patients, statins are contraindicated, and alternative lipid-lowering strategies should be considered. Option A (Age) is incorrect because although older age increases susceptibility to myopathy, it is not a direct causative factor. Option B (Erythromycin interaction) is correct as it directly leads to increased statin levels and subsequent muscle toxicity. Other options, if provided, would similarly be less specific in explaining the necrotizing myositis in this context. 1. Always review drug interactions in patients presenting with statin-associated muscle symptoms. 2. CYP3A4 inhibitors like erythromycin can significantly elevate statin levels, leading to severe myopathy. 3. The spectrum of statin-induced muscle injury ranges from mild myalgia to life-threatening necrotizing myositis. Recent guidelines and pharmacovigilance studies have reinforced the risk of drug interactions with statins. Updated recommendations advise clinicians to avoid the concurrent use of potent CYP3A4 inhibitors in patients taking statins, especially in populations at higher risk for adverse effects.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario or hypokalemic PP, low K 2.3 treated asking about tx",
    "option_a": "(Acetazolamide) is typically reserved for prophylaxis and may even worsen attacks in certain genetic subtypes. Option B (Spironolactone) is a potassium",
    "option_b": "",
    "option_c": "(Daily potassium supplementation) is correct for the acute management, as it directly addresses the underlying hypokalemia.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "This question evaluates the appropriate treatment of an acute episode of hypokalemic periodic paralysis (HypoPP), a channelopathy characterized by episodic muscle weakness during periods of low serum potassium. HypoPP is commonly linked to mutations affecting voltage-gated calcium or sodium channels in skeletal muscle. During an attack, a sudden drop in serum potassium leads to altered membrane excitability, rendering the muscle fibers unresponsive and causing paralysis. Clinically, patients present with acute episodes of generalized muscle weakness, often triggered by factors such as high-carbohydrate meals or strenuous exercise. The key laboratory finding is a significantly low serum potassium level, as seen in this case with a level of 2.3 mEq/L. The diagnosis is based on clinical history and documented hypokalemia during an episode. Differential diagnoses include hyperkalemic periodic paralysis (with high potassium during attacks), thyrotoxic periodic paralysis, and other neuromuscular disorders. Measurement of serum electrolytes during the symptom period is essential to accurately categorize the type of periodic paralysis. For an acute attack of hypokalemic periodic paralysis, the first-line treatment is oral potassium supplementation, which helps restore normal muscle membrane potential. Prophylactic treatment may include agents like acetazolamide; however, it is not used for treating an acute attack. In pregnant or lactating patients, potassium supplementation remains the safest option, with careful monitoring of serum levels to avoid hyperkalemia. Option A (Acetazolamide) is typically reserved for prophylaxis and may even worsen attacks in certain genetic subtypes. Option B (Spironolactone) is a potassium-sparing diuretic but is not well established for the acute management of HypoPP. Option C (Daily potassium supplementation) is correct for the acute management, as it directly addresses the underlying hypokalemia. 1. Acute management of HypoPP hinges on the immediate correction of low serum potassium. 2. Acetazolamide is useful primarily as a prophylactic agent and may be contraindicated in some genetically determined forms of HypoPP. 3. Always tailor potassium supplementation carefully, especially in patients with cardiovascular risks. Recent clinical guidelines continue to advocate for oral potassium supplementation as the first-line treatment during acute hypokalemic episodes. Emerging research also underscores the importance of genetic testing to guide long-term management, particularly regarding the use of prophylactic agents such as acetazolamide.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario suggest of Periodic paralysis (filipino guy with generalized muscle weakness) asking about next investigation",
    "option_a": "(Serum potassium level measurement) is correct because it directly assesses the underlying metabolic disturbance driving the periodic paralysis. Other investigations such as electromyography, muscle biopsy, or genetic testing may be used adjunctively, but they are not as immediately informative in the acute setting.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses the diagnostic workup in a patient with suspected periodic paralysis. A serum potassium level measurement is the cornerstone of the initial evaluation, as it helps to differentiate between hypokalemic and hyperkalemic forms of the condition. Periodic paralyses are channelopathies that lead to episodic muscle weakness. In hypokalemic periodic paralysis, mutations result in abnormal ion channel function that causes potassium to shift intracellularly during an attack, leading to a low serum potassium level and muscle fiber inexcitability. Patients typically present with acute episodes of generalized or proximal muscle weakness. The clinical manifestations correlate with the degree of potassium abnormality. A timely measurement of serum potassium during an episode is crucial for accurate diagnosis and management. The first step in evaluating suspected periodic paralysis is to measure the serum potassium level during an attack. Differential diagnoses include other forms of muscle weakness such as myasthenia gravis, Guillain\u2013Barr\u00e9 syndrome, or electrolyte disturbances from other causes. However, the characteristic fluctuation of potassium levels strongly supports a diagnosis of periodic paralysis. After confirming the diagnosis with serum electrolyte testing, management focuses on correcting the potassium imbalance. In the acute phase, potassium supplementation is indicated, and long-term management may involve avoiding triggers, lifestyle modifications, and possible prophylactic medications (e.g., acetazolamide, with caution in certain genetic variants). In pregnancy and lactation, careful electrolyte monitoring and conservative potassium replacement are recommended to avoid fetal/neonatal complications. Option A (Serum potassium level measurement) is correct because it directly assesses the underlying metabolic disturbance driving the periodic paralysis. Other investigations such as electromyography, muscle biopsy, or genetic testing may be used adjunctively, but they are not as immediately informative in the acute setting. 1. Always obtain serum electrolytes during an acute attack of suspected periodic paralysis. 2. The potassium level during an attack is diagnostic and directs both acute and long-term management strategies. 3. Differentiating between hypokalemic and hyperkalemic periodic paralysis is essential for effective treatment. Recent research and updated clinical guidelines emphasize prompt serum potassium testing during episodes of periodic paralysis. Advanced genetic testing may follow for definitive diagnosis, but the initial, cost-effective, and rapid serum potassium measurement remains the recommended first step in the diagnostic workup.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "What goes with anti musk",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti-MuSK myasthenia gravis (MG) is a subtype of the autoimmune disorder MG where antibodies are directed against muscle-specific kinase (MuSK). This antibody-mediated disruption affects the clustering of acetylcholine receptors at the neuromuscular junction. Unlike the more common AChR-antibody positive MG, anti-MuSK MG has distinct clinical and immunogenetic features. Anti-MuSK antibodies, predominantly of the IgG4 subclass, interfere with MuSK\u2019s normal role in maintaining the architecture of the neuromuscular junction. The strong HLA association\u2014particularly with alleles such as HLA-DRB3 and HLA-B8\u2014underscores a genetic susceptibility that plays a role in the disease\u2019s immune pathogenesis. Clinically, patients with anti-MuSK MG often present with bulbar muscle weakness (e.g., dysarthria, dysphagia), respiratory challenges, and involvement of neck and limb muscles. The immunogenetic profile (HLA-DRB3 and HLA-B8) helps differentiate it from AChR-positive MG, which may present with more prominent ocular symptoms. Diagnosis is established by a combination of clinical features, serologic testing for anti-MuSK antibodies, electrophysiologic studies such as repetitive nerve stimulation and single-fiber electromyography, and sometimes imaging. Differential diagnoses include seronegative MG and Lambert-Eaton myasthenic syndrome, but serology and HLA associations help narrow the diagnosis. Management generally involves immunosuppressive therapy. First-line treatments include corticosteroids and other immunosuppressants (e.g., azathioprine), while cholinesterase inhibitors may be used symptomatically though they might be less effective in anti-MuSK MG. In crisis situations, plasmapheresis or IVIG can be considered. For pregnant or lactating patients, corticosteroids remain relatively safe while other immunosuppressants require a careful risk-benefit analysis with close monitoring. Option (b) is correct because anti-MuSK MG has been strongly linked with HLA-DRB3 and HLA-B8. In contrast, option (a) citing normal thyroid function is irrelevant in this immunogenetic context. The other options (not listed) do not capture the key HLA association seen in anti-MuSK MG. 1. Anti-MuSK MG typically presents with marked bulbar weakness and may respond less well to cholinesterase inhibitors. 2. The HLA-DRB3 and HLA-B8 association is a distinguishing immunogenetic marker. 3. Accurate serologic testing is essential for subtype-specific management in MG. Recent studies reinforce the relevance of HLA typing in anti-MuSK MG, and updated guidelines stress tailoring immunosuppressive regimens based on antibody status. Current research continues to explore optimal management strategies with a focus on individualized patient care.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario about IBM tx",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Inclusion body myositis (IBM) is an idiopathic inflammatory myopathy that primarily affects older adults. It is characterized by a combination of inflammatory and degenerative muscle changes leading to progressive weakness. IBM involves muscle fiber degeneration with classic pathological features including rimmed vacuoles, amyloid deposition, and endomysial inflammation. Unlike other inflammatory myopathies, IBM also exhibits degenerative changes that contribute to its refractoriness to immunosuppressive treatments. Patients with IBM typically present with a slow, progressive weakness that predominantly affects the quadriceps and deep finger flexors. Dysphagia can occur and the condition is notable for its poor response to typical immunosuppressive therapies, which distinguishes it from polymyositis or dermatomyositis. Diagnosis involves clinical evaluation supported by elevated (but only mildly) creatine kinase levels, electromyography showing myopathic changes, and muscle biopsy that reveals rimmed vacuoles, amyloid deposits, and inflammatory infiltrates. Differential diagnoses include polymyositis, dermatomyositis, and other myopathies; however, the pattern of weakness and biopsy findings are highly indicative of IBM. The primary treatment for IBM is supportive care. First-line management includes physical therapy, occupational therapy, and the use of assistive devices to maintain function and quality of life. Immunosuppressive therapies such as corticosteroids, IVIG, or other disease-modifying agents are ineffective and are generally not recommended. In pregnancy and lactation, supportive care remains the cornerstone of management, as immunosuppressive agents carry risks that outweigh benefits in this context. Option (a) 'Supportive' is correct because no current immunosuppressive or disease-modifying therapy has been proven effective for IBM. Other options, such as corticosteroids, IVIG, or experimental immunosuppressants, have not demonstrated benefit in clinical studies and may expose patients to unnecessary side effects. 1. IBM is the most common inflammatory myopathy in individuals over 50. 2. It is characteristically resistant to immunosuppressive therapy. 3. Supportive care is the cornerstone of management, aiming to preserve function and quality of life. Current guidelines and recent clinical studies consistently show that immunosuppressive agents do not alter the course of IBM, highlighting the importance of supportive measures. Ongoing research is focused on novel therapeutic targets, but at present, supportive treatment remains the standard of care.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario about dysferlin CK up35X, mild upper limb weakness mainly LL and significant calf atrophy weak dorsiflexion dx",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dysferlinopathies are a group of muscular dystrophies that include conditions such as Miyoshi myopathy (LGMD2B) and limb-girdle muscular dystrophy type 2B. These disorders result from mutations in the dysferlin gene, leading to defective repair of the muscle membrane. Mutations in the dysferlin gene disrupt the normal repair mechanism of muscle fibers, causing them to degenerate over time. This leads to progressive muscle weakness and atrophy. In Miyoshi myopathy, the presentation is more pronounced in the distal muscles, particularly the calf muscles. Patients with Miyoshi myopathy typically present with markedly elevated creatine kinase levels (often 35 times normal), significant calf atrophy, and weakness in dorsiflexion. The pattern of muscle involvement, with milder upper limb weakness and prominent lower limb symptoms, is characteristic of dysferlinopathy. The diagnosis is based on clinical presentation, serum CK levels, electromyography, and muscle biopsy showing dystrophic changes. Genetic testing confirming dysferlin mutations is the definitive diagnostic tool. Differential diagnoses include Duchenne and Becker muscular dystrophies and facioscapulohumeral muscular dystrophy, which have distinct clinical features and different patterns of muscle involvement. There is no cure for dysferlinopathy; management is supportive. First-line treatment involves physical therapy and occupational therapy to maintain mobility and function, along with the use of assistive devices. Research into gene therapies and other molecular interventions is ongoing. For pregnant or lactating patients, management remains supportive with careful monitoring to avoid excessive strain on muscle function. Option (a) \u2018Myoshi (LGMD2b)\u2019 is correct because the clinical findings\u2014high CK, significant calf atrophy, and weakness in dorsiflexion\u2014are most consistent with Miyoshi myopathy, a variant of dysferlinopathy. Other options such as Duchenne, Becker, or facioscapulohumeral dystrophy are excluded based on differences in age of onset, pattern of weakness, and genetic inheritance. 1. Dysferlin mutations impair the muscle\u2019s ability to repair itself. 2. Miyoshi myopathy typically presents with distal muscle involvement including significant calf atrophy. 3. Genetic testing is crucial for a definitive diagnosis in suspected dysferlinopathies. Recent advancements emphasize the role of genetic testing in confirming dysferlinopathies. Research into targeted therapies, including gene therapy, is emerging but remains experimental; hence, the standard management continues to be supportive care.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario about clapine with eosinophil on pathology",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Eosinophilic myopathies can occur as a result of idiopathic inflammatory conditions or as drug-induced phenomena. Although the term 'calpainopathy' traditionally refers to a genetic myopathy (LGMD2A) due to calpain 3 mutations, in this context the question appears to address a myopathy associated with eosinophilic infiltration on pathology\u2014likely in the setting of drug exposure. In drug-induced eosinophilic myopathy, an immune-mediated hypersensitivity reaction leads to an inflammatory infiltrate rich in eosinophils within the muscle tissue. While classic calpainopathies are genetic, the use of the term here may reflect a semantic or typographical overlap with a drug-induced process that results in similar pathological findings. Patients may present with muscle weakness and sometimes myalgias after exposure to an offending agent. The presence of eosinophils on muscle biopsy is a key feature in differentiating this process from other inflammatory myopathies, which typically show lymphocytic predominance. Diagnosis is confirmed with a muscle biopsy demonstrating eosinophilic infiltration. Differential diagnoses include polymyositis (which has lymphocytic infiltrates), eosinophilic fasciitis, and parasitic myositis. A thorough medication history is critical to establish a drug-induced cause. The primary management strategy is discontinuation of the offending drug, with supportive care provided as needed. In more severe cases, corticosteroids may be employed to reduce inflammation. In pregnant or lactating patients, the risk-benefit ratio of corticosteroid use should be carefully considered, and non-pharmacologic supportive measures are preferred where possible. Option (a) is considered correct in this scenario based on the provided explanation. Although 'calpainopathy' typically refers to a genetic disorder (LGMD2A), in the context of this question it appears to denote a myopathy characterized by eosinophilic infiltration\u2014consistent with a drug-induced hypersensitivity reaction. Other options likely refer to classic inflammatory myopathies that do not feature prominent eosinophilia and thus are less appropriate. 1. Eosinophilic infiltration in muscle biopsy is a red flag for a drug-induced or allergic myopathic process. 2. Discontinuation of the offending agent is paramount in management. 3. A careful medication history is essential in patients presenting with unusual myopathic patterns on biopsy. Emerging research emphasizes the importance of distinguishing drug-induced myopathies from genetic or idiopathic inflammatory myopathies based on both histologic findings and clinical history. Recent reviews advocate for prompt discontinuation of the suspected drug and cautious use of corticosteroids to mitigate symptoms, especially in vulnerable populations such as pregnant or lactating women.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "LGMD1B what to find",
    "option_a": "(\u2018Elbow & ankle contractures\u2019) is correct because these contractures are a well",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "LGMD1B is a subtype of limb\u2010girdle muscular dystrophy, typically associated with mutations in the LMNA gene. It is characterized by proximal muscle weakness, early contractures (commonly at the elbows and ankles), and often cardiac conduction abnormalities. Mutations in the LMNA gene lead to abnormal lamins A and C that play a crucial role in maintaining the nuclear envelope integrity. These defective proteins result in muscle fiber damage, fibrosis, and subsequent contracture formation, particularly affecting the periarticular tissues. Patients with LGMD1B present with slowly progressive proximal muscle weakness accompanied by contractures at sites such as the elbows and ankles. Importantly, cardiac involvement (including conduction defects) may occur. The presence of these contractures distinguishes LGMD1B from other muscular dystrophies that either lack contractures or involve different distributions of weakness. Diagnosis is based on clinical examination, family history, laboratory tests (CK levels are usually normal or mildly elevated), electromyography, muscle imaging, and ultimately confirmed by genetic testing identifying LMNA mutations. Differential diagnoses include other LGMD subtypes and conditions like Emery-Dreifuss muscular dystrophy, which also involves cardiac conduction abnormalities but typically has a different pattern of muscle involvement. Management is supportive and multidisciplinary. First-line strategies include physical therapy to maintain joint mobility and strength, orthotic devices to manage contractures, and regular cardiac evaluations (including EKG and echocardiography). There is no cure. In cases of cardiac involvement, interventions may include pacemaker implantation. In pregnancy, careful cardiovascular monitoring is essential. Lactating women should be managed conservatively with emphasis on multidisciplinary care. Option A (\u2018Elbow & ankle contractures\u2019) is correct because these contractures are a well-recognized hallmark of LGMD1B. The presence of such contractures, along with proximal weakness and potential cardiac conduction defects, helps to differentiate LGMD1B from other neuromuscular disorders. Other options (if provided) such as isolated distal weakness, facial predominance, or severe CK elevation would not align with the typical presentation of LGMD1B. 1. Elbow and ankle contractures are a distinguishing feature in LGMD1B. 2. Cardiac conduction defects are common and warrant regular evaluation. 3. CK levels are usually normal or only mildly elevated despite significant clinical findings. Recent updates emphasize genetic confirmation of LMNA mutations in patients with ambiguous clinical phenotypes. Current research is exploring gene-based therapies and targeted interventions that may modify disease progression in the future.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Long face, central core on pathology",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "(Central Core Disease) is correct. Alternative options such as Nemaline Myopathy (which presents with rod",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Central Core Disease (CCD) is a congenital myopathy that is classically associated with distinctive muscle biopsy findings\u2014namely, central cores\u2014and a characteristic facial phenotype including a long face. CCD is most often related to mutations in the RYR1 gene, which encodes the ryanodine receptor involved in calcium release from the sarcoplasmic reticulum. These mutations result in cores within muscle fibers, which appear as regions devoid of mitochondria and oxidative enzyme activity. Patients with CCD typically present with hypotonia, muscle weakness (often mild to moderate), and a long, narrow face. The central cores seen on histopathology are pathognomonic. In addition, these patients may have an increased risk for malignant hyperthermia, an important consideration for anesthesia. Diagnosis is based on clinical presentation, muscle imaging, and confirmatory muscle biopsy demonstrating central cores. Genetic testing for RYR1 mutations further supports the diagnosis. Differential diagnoses include nemaline myopathy (which shows rod-like inclusions), multiminicore disease (multiple small cores), and centronuclear myopathy (central nuclei rather than cores). Management is primarily supportive. First-line treatment includes physical and occupational therapy to optimize motor function and reduce contractures. Patients should be evaluated for malignant hyperthermia susceptibility before surgical procedures. In pregnancy, careful monitoring is warranted due to the potential for anesthesia-related complications. Lactating women should be counseled on the benign nature of the condition regarding milk production, although therapy remains supportive. Option D (Central Core Disease) is correct. Alternative options such as Nemaline Myopathy (which presents with rod-like inclusions on biopsy), Multiminicore Disease (characterized by multiple, small cores), Centronuclear Myopathy (defined by centrally placed nuclei), and Dystrophinopathy (which involves dystrophin deficiency) do not match the key findings of a central core on pathology combined with the long face phenotype. 1. Central cores on muscle biopsy are pathognomonic for CCD. 2. A long face is a characteristic clinical feature that supports the diagnosis. 3. Always consider malignant hyperthermia risk in these patients. Recent research continues to underscore the role of RYR1 mutations in CCD. Updated guidelines stress the importance of genetic testing for accurate classification. There is also increased awareness about the susceptibility to malignant hyperthermia, leading to more cautious anesthetic management.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has myotonia symptoms since age 10 for 5 years, father had myotonia, no mention of weakness, what",
    "option_a": "(Thomsen disease) is correct given the presentation: childhood onset, isolated myotonia, and a clear autosomal dominant inheritance pattern. Other options, such as myotonic dystrophy, are less likely because they are typically accompanied by progressive weakness and multisystem involvement.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a classical presentation of autosomal dominant myotonia congenita, known as Thomsen disease. It is characterized primarily by myotonia without significant muscle weakness and follows an autosomal dominant inheritance pattern. Thomsen disease is caused by mutations in the CLCN1 gene that encodes the skeletal muscle chloride channel. The resultant defect prolongs the depolarization phase of the muscle membrane, causing delayed relaxation (myotonia) following contraction. The patient\u2019s history of myotonia since childhood, along with a positive paternal history, strongly suggests an autosomal dominant pattern consistent with Thomsen disease. The absence of weakness further differentiates it from other myotonic disorders, such as myotonic dystrophy, which typically involve multisystem manifestations and progressive weakness. Diagnosis is predominantly clinical, supported by electromyography (EMG) that shows characteristic myotonic discharges. Genetic testing can confirm mutations in the CLCN1 gene. Differential diagnoses include myotonic dystrophy (which presents with systemic features like cataracts, cardiac conduction abnormalities, and endocrine dysfunction) and paramyotonia congenita (which may have cold-induced symptoms). First-line management involves symptomatic treatment with sodium channel blockers such as mexiletine, which has been shown to improve myotonia. Physical therapy can be supportive. In pregnancy, mexiletine is considered category C and should be used if the benefits outweigh the risks, with close monitoring. Lactating mothers should be counseled regarding potential drug excretion in breast milk and monitored appropriately. Option A (Thomsen disease) is correct given the presentation: childhood onset, isolated myotonia, and a clear autosomal dominant inheritance pattern. Other options, such as myotonic dystrophy, are less likely because they are typically accompanied by progressive weakness and multisystem involvement. 1. Isolated myotonia with minimal weakness suggests myotonia congenita rather than myotonic dystrophy. 2. A positive family history in an autosomal dominant pattern is key to diagnosing Thomsen disease. 3. EMG findings of myotonic discharges support the diagnosis. Recent studies reinforce the efficacy of mexiletine in reducing myotonia symptoms. Genetic testing has become a cornerstone in differentiating myotonic disorders, and ongoing research is exploring novel therapies targeting channelopathies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about botulism with increment on high frequency RNS what pathology",
    "option_a": "(\u2018Prevent acetylcholine release from presynaptic vesicles\u2019) is correct because it accurately describes the mechanism by which botulinum toxin exerts its effect. Other potential mechanisms (such as postsynaptic receptor blockade, receptor destruction, or muscle membrane depolarization issues) do not explain the facilitation seen on high",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Botulism is a severe neuroparalytic condition resulting from exposure to botulinum toxin, an exotoxin produced by Clostridium botulinum. Its primary mechanism involves disruption of neuromuscular transmission. The toxin cleaves SNARE proteins (such as SNAP-25, synaptobrevin, and syntaxin) in the presynaptic nerve terminals, which prevents the fusion of acetylcholine-containing vesicles with the presynaptic membrane. The resulting blockade of acetylcholine release at the neuromuscular junction leads to a flaccid paralysis that is characteristic of botulism. Clinically, botulism presents with a descending symmetric weakness, blurred vision, dysphagia, and potential respiratory compromise. Electrophysiological studies, typically showing facilitation (increment) on high-frequency repetitive nerve stimulation (RNS), further support a presynaptic defect in neuromuscular transmission. Diagnosis relies on clinical suspicion supported by electrophysiological studies and laboratory confirmation of the botulinum toxin. Differential diagnoses include myasthenia gravis and Lambert-Eaton myasthenic syndrome. In myasthenia gravis, the defect is postsynaptic (leading to decrement on low-frequency RNS), whereas Lambert-Eaton syndrome (a presynaptic disorder) usually shows incremental response on low-frequency stimulation and is associated with malignancy. Immediate administration of antitoxin is the cornerstone of management and should be initiated as soon as possible, even in pregnant patients, as the risk of progression outweighs potential risks. Supportive care, including respiratory support in an intensive care setting, is crucial. Pregnant and lactating patients should receive antitoxin and supportive care as indicated, with multidisciplinary monitoring for maternal and neonatal outcomes. Option A (\u2018Prevent acetylcholine release from presynaptic vesicles\u2019) is correct because it accurately describes the mechanism by which botulinum toxin exerts its effect. Other potential mechanisms (such as postsynaptic receptor blockade, receptor destruction, or muscle membrane depolarization issues) do not explain the facilitation seen on high-frequency RNS and do not align with the known toxin action. 1. Botulinum toxin causes a presynaptic blockade by cleaving SNARE proteins. 2. High-frequency RNS showing facilitation is a hallmark of presynaptic defects. 3. Early antitoxin administration is critical in reducing morbidity and mortality. Current guidelines emphasize the importance of rapid diagnosis and antitoxin administration. Recent research continues to evaluate optimal supportive strategies and the potential role of novel therapeutic agents in mitigating toxin effects. Studies also focus on refining electrophysiological testing protocols for earlier detection of neuromuscular blockade.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "20 yr with respiratory symptoms, aneurysm, PAS on pathology, neg forearm exercise dx, no clinical but electrical myotonia",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This clinical vignette describes a 20\u2010year\u2010old patient presenting with predominant respiratory symptoms, an aneurysm, and a muscle biopsy that shows PAS-positive inclusions. In addition, the diagnostic workup includes a negative forearm exercise test and the finding of electrical (but not clinical) myotonia on EMG. These features are most consistent with late-onset Pompe disease (glycogen storage disease type II), where the accumulation of glycogen in lysosomes produces PAS-positive vacuoles without the typical clinical myotonia seen in other channelopathies. Pompe disease is a lysosomal storage disorder caused by a deficiency of acid alpha-glucosidase due to mutations in the GAA gene. This results in the accumulation of glycogen within lysosomes, particularly in cardiac and skeletal muscle. The consequent cellular damage leads to muscle fiber dysfunction and can be associated with vascular abnormalities such as aneurysms in some cases. Patients with late-onset Pompe disease typically develop a slowly progressive myopathy involving the proximal and respiratory muscles. Respiratory insufficiency may precede significant limb weakness. Although clinical myotonia (i.e., delayed muscle relaxation) is not usually apparent, electrical myotonia can be detected on electromyography, indicating membrane hyperexcitability. The presence of PAS-positive vacuoles on muscle biopsy is a hallmark of this disease. Key differentials include other metabolic myopathies such as McArdle disease (glycogen storage disease type V), which would usually give an abnormal forearm exercise test due to its defect in muscle glycogen phosphorylase and present with exercise intolerance. Myotonic dystrophies are another consideration; however, they typically demonstrate overt clinical myotonia and distinct histopathologic features. Confirmatory diagnosis of Pompe disease is established by measuring acid alpha-glucosidase enzyme activity and genetic testing for GAA mutations. The mainstay of treatment for Pompe disease is enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase (alglucosidase alfa), which has been shown to improve or stabilize muscle strength and respiratory function. Supportive care with physical therapy, respiratory support, and cardiac monitoring is crucial. In pregnant or lactating patients, ERT should be evaluated on a case\u2010by\u2010case basis after multidisciplinary counseling, although available evidence suggests that the benefits may outweigh the potential risks if the disease is active and therapy is essential. Even though the complete list of options is not provided, the combination of respiratory involvement, PAS-positive vacuoles, a negative forearm exercise test, and the presence of electrical (but not clinical) myotonia best fits the diagnosis of late-onset Pompe disease. Other options such as McArdle disease or myotonic dystrophy would typically show different biochemical, histopathologic, or clinical findings. \u2022 Always consider Pompe disease in young adults presenting with respiratory muscle weakness and atypical findings on muscle biopsy (PAS positivity). \n\u2022 A negative forearm exercise test helps differentiate Pompe disease from other metabolic myopathies like McArdle disease. \n\u2022 Electrical myotonia, in the absence of clinical myotonia, can be a subtle electrophysiological clue in Pompe disease. \n\u2022 Be aware that vascular anomalies, such as aneurysms, although not common, can be seen in Pompe disease cases. Recent guidelines and studies support early initiation of ERT in Pompe disease to improve long-term outcomes. Current research is focused on optimizing dosing schedules, improving enzyme stability, and exploring adjunct therapies. There is also ongoing evaluation of the safety profile of ERT during pregnancy and lactation, with the consensus favoring individualized management given the potential risks of untreated progressive disease.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Infant with respiratory, electrical myotonia, macroglosia",
    "option_a": ", which was marked as the answer, corresponds to congenital myotonic dystrophy. Despite the incomplete list of options provided, the combination of respiratory involvement, electrical myotonia on EMG, and macroglossia is classically seen in congenital myotonic dystrophy type 1. Other options, if provided, may have included alternative differential diagnoses, but none would account for the specific finding of electrical myotonia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "The infant\u2019s presentation with respiratory difficulties, electrical myotonia (demonstrated on electromyographic studies), and macroglossia is most consistent with congenital myotonic dystrophy type 1. This disorder is typically due to a CTG repeat expansion in the DMPK gene and is inherited in an autosomal dominant fashion with a strong maternal transmission bias that can lead to a more severe neonatal presentation. Congenital myotonic dystrophy type 1 arises from an unstable CTG trinucleotide repeat expansion in the DMPK gene. The pathogenic process involves expression of toxic mRNA that disrupts the function and splicing of various proteins. This abnormal splicing leads to the multisystem manifestations of the disorder, including myotonia, skeletal muscle weakness, respiratory insufficiency, and occasionally macroglossia. In neonates, congenital myotonic dystrophy may present with hypotonia, respiratory distress, and feeding difficulties. Electrical myotonia, which is often detected on electromyography as characteristic myotonic discharges (a dive-bomber sound), reinforces the diagnosis. Although macroglossia can be seen in other conditions (e.g., Beckwith-Wiedemann syndrome and hypothyroidism), the presence of electrical myotonia strongly favors a myotonic dystrophy diagnosis. The diagnosis is based on clinical findings supported by electromyography to detect electrical myotonia. Genetic testing confirming the CTG repeat expansion in the DMPK gene is definitive. Differential diagnoses to consider include other causes of neonatal hypotonia such as congenital hypothyroidism or metabolic disorders, but those conditions do not typically exhibit electrical myotonia. Management of congenital myotonic dystrophy is multidisciplinary and supportive. Respiratory support (including possible mechanical ventilation), feeding assistance, and early physiotherapy are key. Cardiologic evaluations should be performed as conduction abnormalities can occur. In the context of pregnancy and lactation, genetic counseling is crucial due to the high risk of transmission and anticipation. Maternal management should involve careful monitoring during pregnancy, with attention to complications such as polyhydramnios, and planning for appropriate neonatal support post-delivery. Option A, which was marked as the answer, corresponds to congenital myotonic dystrophy. Despite the incomplete list of options provided, the combination of respiratory involvement, electrical myotonia on EMG, and macroglossia is classically seen in congenital myotonic dystrophy type 1. Other options, if provided, may have included alternative differential diagnoses, but none would account for the specific finding of electrical myotonia. 1. Electrical myotonia on EMG is a critical diagnostic clue in neonates with suspected myotonic dystrophy. 2. Macroglossia, while seen in other disorders, in conjunction with myotonia should steer clinicians toward a diagnosis of congenital myotonic dystrophy. 3. Maternal history is often revealing, given the phenomenon of anticipation; mothers may have a milder phenotype but pass on a more severe neonatal form. Recent guidelines emphasize a supportive, multidisciplinary approach to congenital myotonic dystrophy. Advances in genetic testing and prenatal diagnostics allow for earlier detection. In pregnancy, mothers with myotonic dystrophy require careful obstetric monitoring owing to risks such as polyhydramnios and preterm labor. Postnatal management is largely symptomatic, focusing on optimizing respiratory and nutritional status, with evolving research into targeted molecular therapies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Ocular muscle weakness, ptosis with Mild facial weakness, proximal weakness",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical presentation \u2013 ocular muscle weakness with ptosis, along with mild facial and proximal limb weakness \u2013 is most characteristic of Myasthenia Gravis (MG). MG is an autoimmune disorder that primarily affects the neuromuscular junction, leading to variable muscle weakness, particularly in muscles that are used frequently, such as those controlling the eyes and face. In MG, autoantibodies (commonly IgG type against acetylcholine receptors) impair neuromuscular transmission by either blocking, modulating, or destroying the receptors at the postsynaptic neuromuscular junction. This reduction in available acetylcholine receptors causes the hallmark fluctuating muscle weakness that worsens with repeated use and improves with rest. Patients with MG often present with ocular symptoms (ptosis, diplopia) that may progress to involve facial and proximal limb muscles. The key clinical clue is the fluctuating nature of the weakness, frequently worsening at the end of the day or after sustained muscle use. These features help differentiate MG from other neuromuscular disorders. The diagnosis of MG typically involves clinical evaluation, supported by diagnostic tests such as: The management of MG involves both symptomatic and immunomodulatory treatments. Key strategies include:\n- Acetylcholinesterase inhibitors (e.g., pyridostigmine) for symptomatic relief. Pyridostigmine is generally considered safe in pregnancy and lactation.\n- Immunosuppressive therapies (e.g., corticosteroids, azathioprine) to control the autoimmune process. In pregnant patients, the risks and benefits need careful balancing; often, lower doses or alternative agents may be considered.\n- Thymectomy may be indicated in appropriate patients, particularly younger individuals with thymic hyperplasia or thymoma.\n- In cases of myasthenic crisis, rapid interventions including plasmapheresis or intravenous immunoglobulin (IVIG) may be necessary.\nRecent guidelines emphasize individualized treatment approaches with careful monitoring during pregnancy and lactation to ensure both maternal disease control and fetal safety. Although the complete list of options is not provided, the clinical presentation strongly suggests MG as the underlying diagnosis. Options like Lambert-Eaton Myasthenic Syndrome, muscular dystrophies, or mitochondrial disorders were less likely based on the described pattern. The marked answer A, which is presumed to represent Myasthenia Gravis, is therefore correct. \u2022 MG often presents with ocular symptoms such as ptosis and diplopia that may be the initial or even sole manifestation.\n\u2022 A fluctuating pattern of weakness, worsening with exertion and improving with rest, is highly suggestive.\n\u2022 Early recognition and testing for autoantibodies are crucial.\n\u2022 Management requires a balance of symptomatic relief and immune suppression, with special considerations during pregnancy and lactation. Current research continues to refine the treatment protocols for MG with advances in immunotherapy, including the use of targeted monoclonal antibodies (e.g., eculizumab) for refractory cases. Standard therapy remains centered on acetylcholinesterase inhibitors and immunosuppressive agents. Multidisciplinary care, especially for women of childbearing age, is essential to optimize outcomes during pregnancy and lactation.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "female with hx of neuropathic ulcer, Testing for PMP22 deletion and duplication -ve What is the gene",
    "option_a": "IK",
    "option_b": "T",
    "option_c": "",
    "option_d": "SPLECT",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary peripheral neuropathies are a heterogeneous group of disorders that can manifest with chronic sensory deficits leading to complications such as neuropathic ulcers. In patients suspected of Charcot\u2010Marie\u2013Tooth (CMT) disease, testing for PMP22 duplication (CMT1A) or deletion (HNPP) is often the first step. When PMP22 testing is negative in a patient with a neuropathic ulcer, one must consider other genetic causes such as those underlying Hereditary Sensory and Autonomic Neuropathies (HSAN). In HSAN type I, for example, mutations in the SPTLC1 gene (which \u2013 in this question \u2013 appears to be represented by option D \u201cSPLECT\u201d) lead to a predominantly sensory neuropathy with ulcerations owing to loss of protective pain sensation. In HSAN type I, mutations in SPTLC1 disrupt the normal function of serine palmitoyltransferase, a key enzyme in sphingolipid metabolism. Abnormal sphingolipid levels cause degeneration of small sensory and autonomic fibers. This leads to impaired nociception and diminished protective responses, thereby predisposing patients to repeated trauma and non\u2010healing neuropathic ulcers. Patients with HSAN type I typically present in adolescence or early adulthood with a progressive loss of pain and temperature sensation in the distal extremities. The resultant unnoticed repetitive trauma and consequent foot ulcers can mimic common diabetic or other neuropathic ulcers. A history of neuropathic ulcer in a female patient, with negative PMP22 deletion/duplication testing, raises suspicion for an alternative genetic etiology such as an SPTLC1 mutation. The differential diagnosis for a patient with neuropathic ulcers includes diabetic neuropathy, various forms of CMT, and HSAN disorders. After ruling out PMP22-related CMT (by demonstrating the absence of PMP22 duplication or deletion), further evaluation with nerve conduction studies, detailed neurological assessments, and expanded genetic testing (including sequencing of SPTLC1) is recommended to confirm HSAN type I. Management is largely supportive. Preventive foot care, use of protective footwear, regular wound assessments, and early intervention in case of skin breakdown are essential to prevent complications. Pain management and physical therapy play roles in improving function. Genetic counseling is recommended. In pregnancy and lactation, management should be conservative, emphasizing non\u2010pharmacologic measures for neuropathic pain and wound care, with medications chosen only after careful risk\u2013benefit analysis in consultation with specialists. Among the options offered \u2013 A: IK, B: T, C: (blank), and D: SPLECT \u2013 option D is the only one that corresponds (albeit in an abbreviated or misspelled form) to a gene implicated in hereditary neuropathies with prominent sensory loss (i.e., HSAN type I due to SPTLC1 mutation). Options A and B do not correspond to established gene names in this context. \u2022 A negative PMP22 test in a patient with neuropathic ulcers should prompt consideration of other hereditary neuropathies such as HSAN type I.  \u2022 HSAN type I is commonly due to an SPTLC1 mutation, which may be represented here as 'SPLECT'.  \u2022 Early diagnosis and proper foot care are crucial to prevent complications.  \u2022 In managing such conditions, particularly in pregnant and lactating patients, non\u2010pharmacological interventions and careful multidisciplinary coordination are key. Recent studies and updated genetic guidelines underscore the importance of extended genetic panels in peripheral neuropathy when initial tests (eg, PMP22 duplication/deletion) are negative. Emerging research continues to explore the molecular pathways of sphingolipid metabolism in HSAN, reinforcing the role of SPTLC1 mutations. Consensus guidelines recommend genetic counseling and personalized management strategies, including special considerations for women during pregnancy and lactation.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]